FPF
MACK

FNY Partners Fund’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

FNY Partners Fund’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-441
Closed -$10K – 1429
2017
Q1 		$10K Buy
+441
New +$11K ﹤0.01% 1103

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

FNY Partners Fund's MACK Position: Q2 2017 in Review

FNY Partners Fund sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2017, closing a stake of 441 shares — an estimated $10K sold.

FNY Partners Fund first reported a position in MACK in Q1 2017 and held it in 1 quarter. The position peaked at $10K in Q1 2017. 119 funds tracked by Wall St. Rank hold MACK as of Q2 2017.

  • FNY Partners Fund reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • FNY Partners Fund sold 441 Merrimack Pharmaceuticals, Inc. shares in Q2 2017, an estimated $10K.
  • FNY Partners Fund first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2017 and held it in 1 quarter.
  • FNY Partners Fund's Merrimack Pharmaceuticals, Inc. position peaked at $10K in Q1 2017.
  • 119 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2017.

Based on FNY Partners Fund's 13F filing for Q2 2017, filed 10 Aug 2017.